Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding ...

What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly reported third-quarter adjusted profit and revenue that missed expectations, sending its stock tumbling roughly 10% Skyrocketing demand for injectable weight loss and diabetes drugs has ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...